Search
52 result(s) for 'author#Eleftherios P. Diamandis' within BMC
Page 1 of 3
Sort by: Relevance | Date
-
Citation: Clinical Proteomics 2006 2:2015
-
Major milestones in translational oncology
Translational oncology represents a bridge between basic research and clinical practice in cancer medicine. Today, translational research in oncology benefits from an abundance of knowledge resulting from geno...
Citation: BMC Medicine 2016 14:110 -
Comparison of methods to examine the endogenous peptides of fetal calf serum
There is a great desire to relate the patterns of endogenous peptides in blood to human disease and drug response. The best practices for the preparation of blood fluids for analysis are not clear and also rel...
Citation: Clinical Proteomics 2006 2:20167 -
Comparison of protein expression lists from mass spectrometry of human blood fluids using exact peptide sequences versus BLAST
The proteins in blood were all first expressed as mRNAs from genes within cells. There are databases of human proteins that are known to be expressed as mRNA in human cells and tissues. Proteins identified fro...
Citation: Clinical Proteomics 2006 2:BF02752500 -
Abstracts
Citation: Clinical Proteomics 2009 5(Suppl 1):9035 -
Discovery of novel glioma serum biomarkers by proximity extension assay
Gliomas are among the most malignant tumors, with a very poor prognosis. Early diagnosis is highly desirable since it can help implement more effective treatments for smaller tumors, which have not yet extensi...
Citation: Clinical Proteomics 2023 20:12 -
The sweet and sour of serological glycoprotein tumor biomarker quantification
Aberrant and dysregulated protein glycosylation is a well-established event in the process of oncogenesis and cancer progression. Years of study on the glycobiology of cancer have been focused on the developme...
Citation: BMC Medicine 2013 11:31 -
Clinical proteomics
Citation: Clinical Proteomics 2006 2:2011 -
Correction to: A proteome-wide immuno-mass spectrometric identification of serum autoantibodies
In the original version of the article [1], an error was noticed under the heading “Immunoprecipitation on protein G magnetic beads” in “Methods” section.
Citation: Clinical Proteomics 2019 16:30 -
Assessment of kallikrein 6 as a cross-sectional and longitudinal biomarker for Alzheimer’s disease
Kallikrein 6 (KLK6) is known to be an age-related protease expressed at high levels in the central nervous system. It was previously shown to be involved in proteolysis of extracellular proteins implicated in ...
Citation: Alzheimer's Research & Therapy 2018 10:9 -
The relationship between serum astroglial and neuronal markers and AQP4 and MOG autoantibodies
Certain demyelinating disorders, such as neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) exhibit serum autoantibodies against aquapori...
Citation: Clinical Proteomics 2024 21:28 -
The democratization of scientific publishing
Where should I submit my paper? This is a question that young scientists and trainees frequently ask. In this Commentary, we advise on how to make such a decision whilst balancing the risks and benefits. We ar...
Citation: BMC Medicine 2019 17:12 -
Semiquantitative proteomic analysis of human hippocampal tissues from Alzheimer’s disease and age-matched control brains
Alzheimer’s disease (AD) is the most common type of dementia affecting people over 65 years of age. The hallmarks of AD are the extracellular deposits known as amyloid β plaques and the intracellular neurofibr...
Citation: Clinical Proteomics 2013 10:5 -
Kallikrein-related peptidases 6 and 10 are elevated in cerebrospinal fluid of patients with Alzheimer’s disease and associated with CSF-TAU and FDG-PET
Alterations in the expression of human kallikrein-related peptidases (KLKs) have been described in patients with Alzheimer’s disease (AD). We elucidated the suitability of KLK6, KLK8 and KLK10 to distinguish A...
Citation: Translational Neurodegeneration 2019 8:25 -
The failure of protein cancer biomarkers to reach the clinic: why, and what can be done to address the problem?
There is a plethora of published cancer biomarkers but the reality is that very few, if any, new circulating cancer biomarkers have entered the clinic in the last 30 years. I here try to explain this apparent ...
Citation: BMC Medicine 2012 10:87 -
The Journal Impact Factor is under attack – use the CAPCI factor instead
The uses and misuses of the Journal Impact Factor (JIF) have been thoroughly discussed in the literature. A few years ago, I predicted that JIF would soon be replaced, while another colleague argued the opposi...
Citation: BMC Medicine 2017 15:9 -
Differential expression of cancer associated proteins in breast milk based on age at first full term pregnancy
First full term pregnancy (FFTP) completed at a young age has been linked to low long term breast cancer risk, whereas late FFTP pregnancy age confers high long term risk, compared to nulliparity. Our hypothes...
Citation: BMC Cancer 2012 12:100 -
Transcriptome profiling and proteomic validation reveals targets of the androgen receptor signaling in the BT-474 breast cancer cell line
Accumulating evidence suggests that the androgen receptor (AR) and its endogenous ligands influence disease progression in breast cancer (BCa). However, AR-mediated changes in BCa differ among the various BCa ...
Citation: Clinical Proteomics 2022 19:14 -
Fascin-1 is a novel biomarker of aggressiveness in some carcinomas
Tremendous progress has been made in recent years towards the understanding, prevention and management of malignant disease, yet cancer remains a leading cause of global mortality and morbidity. Current approa...
Citation: BMC Medicine 2013 11:53 -
A proteome-wide immuno-mass spectrometric identification of serum autoantibodies
Autoantibodies are produced when tolerance to self-antigens is broken and they can be mediators of tissue injury and systemic inflammation. They are excellent biomarkers because they are minimally invasive to ...
Citation: Clinical Proteomics 2019 16:25